Hosted by PeerVoice · 🇺🇸 US · EN-US · 223 episodes
Established thought leaders with verified media credentials.
PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Oncology & Haematology that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.
PeerVoice hosts PeerVoice Oncology & Haematology Video, a science show with 223 episodes published.
Andrea Necchi, MD - Working With Our Patients as a Member of the MDT: A Bladder Cancer Awareness Month 2026 CME Initiative
Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge
Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer
Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings
Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer
Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass
Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey
Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More
Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?
Régis Peffault de Latour, MD, PhD - Stepping Out of the Grey: Beyond Anaemia and Towards Visibility for Patients With PNH
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disea
Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target
Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy
Rachel Soyoun Kim, MD, MHSc, FRCSC - From Evidence to Practice: Combining Immunotherapy With Chemoradiotherapy Regimens in Locally Advanced Cervical Cancer
Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025
Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO
Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC
Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies
Javier Cortés
MD, PhD · International Breast Cancer Center
1 appearance on this show
Laura Huppert
MD
1 appearance on this show
Dr Javier Cortes
Head · International Breast Cancer Centre
1 appearance on this show
Trisha Wise-Draper
MD, PhD
1 appearance on this show
Trisha Wise-Draper
MD, PhD
1 appearance on this show
Austin Kulasekararaj
MD, MRCP, FRCPath
1 appearance on this show
Misty Dawn Shields
MD, PhD
1 appearance on this show
Cristina Saura Manich
MD, PhD
1 appearance on this show
Rebecca Dent
Registered Dietitian
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
PeerVoice Oncology & Haematology Video has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
PeerVoice Oncology & Haematology Video is hosted by PeerVoice. The show is categorised under science (health) and has published 223 episodes.
PeerVoice Oncology & Haematology Video has published 223 episodes.
PeerVoice Oncology & Haematology Video regularly covers science, health, fitness. It sits in the science category, with a health focus.
PeerVoice Oncology & Haematology Video is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
PeerVoice Oncology & Haematology Video hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of PeerVoice Oncology & Haematology Video average 25 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates PeerVoice Oncology & Haematology Video's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 13 days ago.
